What is EurOmega-3 and how does it differ from fish oil?

EurOmega-3 is a standardized chia seed (Salvia hispanica) oil supplying 62–68% ALA, a short-chain plant omega-3, making it a fully vegan alternative to fish oil. Unlike fish oil, which directly provides EPA and DHA, EurOmega-3 requires hepatic conversion of ALA to those longer-chain omega-3s, a process that is inefficient in humans (roughly 5–10% conversion to EPA and under 1% to DHA). This makes it less bioequivalent to fish oil for end-metabolite delivery, but a meaningful option for those avoiding animal-derived products.

What is the recommended dosage of EurOmega-3?

No manufacturer-validated or clinically established dosage specific to EurOmega-3 has been published in peer-reviewed trials. General guidance for ALA supplementation from chia seed oil in preclinical research has used dietary intakes equivalent to approximately 1–3 g of ALA per day in adults. Users should follow label directions provided by the manufacturer and consult a healthcare provider for personalized dosing, especially when managing a specific health condition.

Can EurOmega-3 help reduce inflammation?

EurOmega-3's high ALA content (62–68%) can inhibit COX and LOX enzymes that produce pro-inflammatory prostaglandins and leukotrienes, supporting an anti-inflammatory mechanism at the molecular level. However, this evidence is currently preclinical, derived from cell culture and animal studies rather than human clinical trials, so confirmed anti-inflammatory benefits in people have not yet been demonstrated for this specific extract. For established anti-inflammatory omega-3 outcomes in humans, EPA and DHA from marine sources have a substantially stronger evidence base.

Is EurOmega-3 safe to take with blood thinners?

ALA and its downstream metabolites EPA and DHA can inhibit platelet aggregation and mildly prolong bleeding time, which may potentiate the effects of anticoagulants such as warfarin or antiplatelet agents like clopidogrel. No specific pharmacokinetic interaction studies have been conducted on the EurOmega-3 branded extract with these medications. Individuals taking blood-thinning medications should consult their physician or pharmacist before adding EurOmega-3 to their regimen and may require INR monitoring if on warfarin.

Does EurOmega-3 have any anticancer properties?

Preliminary in vitro research on ALA and chia seed oil has demonstrated pro-apoptotic effects in breast cancer (MCF-7) and colorectal cancer cell lines, linked to modulation of Bcl-2/Bax ratios and oxidative stress pathways. These findings are based on cell-line models using concentrations that may not be achievable through normal supplementation, and no human clinical trials have evaluated EurOmega-3 or chia seed oil specifically for cancer prevention or treatment. The anticancer evidence is therefore considered hypothesis-generating and should not be interpreted as clinical proof of efficacy.

Is EurOmega-3 suitable for vegans and vegetarians?

Yes, EurOmega-3 from Salvia hispanica (chia seeds) is a plant-based omega-3 source, making it suitable for vegans and vegetarians who want to avoid fish-derived supplements. It provides ALA (alpha-linolenic acid), a precursor to EPA and DHA, though conversion rates in humans are typically low. This makes it an accessible option for those following plant-forward diets seeking omega-3 supplementation.

How does the bioavailability of EurOmega-3 compare to other plant-based omega-3 sources?

EurOmega-3 offers a high ALA concentration (62-68% of the oil), making it one of the richest plant-based omega-3 sources available. However, bioavailability depends on processing methods and individual conversion efficiency of ALA to longer-chain omega-3s like EPA and DHA, which varies significantly between individuals. The bioavailable omega-6 to omega-3 ratio in chia seed oil also supports more favorable metabolic balance compared to many other plant sources.

What does current clinical evidence show about EurOmega-3's effectiveness for specific health conditions?

Current evidence for EurOmega-3 is primarily limited to preclinical and in vitro studies, with anti-inflammatory, antidiabetic, and potential anticancer properties identified in laboratory research only. Human clinical trials specifically evaluating EurOmega-3's efficacy are limited, so recommendations should be considered preliminary until more robust clinical data becomes available. The ingredient shows promise based on chia seed composition, but definitive health claims require additional controlled human studies.

EurOmega-3 (Salvia hispanica)

EurOmega-3 is a standardized chia seed (Salvia hispanica) oil extract delivering 62–68% alpha-linolenic acid (ALA), a plant-derived omega-3 fatty acid. ALA exerts anti-inflammatory effects primarily through competitive inhibition of the arachidonic acid cascade and partial hepatic conversion to EPA and DHA.

Category: Other Evidence: 2/10 Tier: Traditional

EurOmega-3 (Salvia hispanica) — Hermetica Encyclopedia

Origin & History

EurOmega-3 (Salvia hispanica) is a branded omega-3 ingredient derived from chia seeds of the plant Salvia hispanica L., an annual herbaceous species in the Lamiaceae family native to Central America. The oil is typically extracted via Soxhlet method using solvents like n-hexane, yielding a lipid-rich product containing 62-68% alpha-linolenic acid (ALA), an essential omega-3 fatty acid.

Historical & Cultural Context

Salvia hispanica (chia) has been used in Mesoamerican traditional medicine systems by the Aztec and Maya civilizations for over 5,000 years, primarily as a staple food and for energy, endurance, and digestive health. It was reintroduced to modern Western diets for its omega-3 benefits.

Health Benefits

• Anti-inflammatory properties from high ALA omega-3 content (62-68% of oil) - evidence quality: preclinical only
• Potential antidiabetic effects suggested by general chia seed research - evidence quality: preclinical contexts only
• Possible anticancer properties indicated in preliminary research - evidence quality: preclinical studies only
• Cardiovascular support through favorable omega-6:omega-3 ratio of 0.3:1 - evidence quality: theoretical based on fatty acid profile
• Antioxidant protection from tocopherols (22.88 µg/mL) and polyphenols - evidence quality: compositional analysis only

How It Works

ALA, the dominant fatty acid in EurOmega-3, competes with arachidonic acid for the cyclooxygenase (COX-1/COX-2) and 5-lipoxygenase (5-LOX) enzymes, reducing synthesis of pro-inflammatory eicosanoids such as prostaglandin E2 and leukotriene B4. A portion of ALA undergoes hepatic desaturation and elongation via delta-6-desaturase (FADS2) and elongase enzymes to yield EPA and DHA, which further resolve inflammation through lipoxin and resolvin pathways. Preliminary cell-based data also suggest ALA and its metabolites may modulate PPAR-alpha and PPAR-gamma nuclear receptors, which could account for reported antidiabetic and antiproliferative signals.

Scientific Research

The research dossier reveals no specific human clinical trials, RCTs, or meta-analyses for EurOmega-3 or standardized Salvia hispanica extracts. No PubMed PMIDs are provided for human studies, with available research limited to compositional analyses and preclinical contexts.

Clinical Summary

Human clinical evidence specific to the EurOmega-3 branded extract is currently absent from the published literature, and available data derive from preclinical (in vitro and rodent) studies on chia seed oil or isolated ALA. Rodent models of type 2 diabetes administered chia seed oil at doses of 5–10% of diet showed improved fasting glucose and insulin sensitivity, though no confirmed human RCT data support these findings for EurOmega-3 specifically. Anticancer signals are limited to cell-line studies demonstrating ALA-induced apoptosis in breast and colorectal cancer cell lines at supraphysiological concentrations, with no human trial evidence. Overall, the evidence quality for EurOmega-3 remains preclinical, and clinical efficacy in humans has not been established.

Nutritional Profile

EurOmega-3 (Salvia hispanica) is a standardized chia seed oil extract with a concentrated fatty acid profile. Primary macronutrient is fat, with ALA (alpha-linolenic acid, an omega-3 fatty acid) comprising 62-68% of total oil content. Omega-6 linoleic acid comprises approximately 18-20% of oil. Oleic acid (omega-9) accounts for approximately 6-8%. Saturated fatty acids (palmitic and stearic) represent approximately 9-11% combined. As an oil extract, it is largely devoid of protein, fiber, and carbohydrates that would be present in whole chia seeds. Whole chia seeds by contrast contain approximately 16-17g protein per 100g, 34g fiber per 100g (soluble and insoluble), and minerals including calcium (~631mg/100g), magnesium (~335mg/100g), phosphorus (~860mg/100g), and zinc (~4.6mg/100g), though these are largely absent in the isolated oil form. Bioactive compounds in the oil include tocopherols (vitamin E isomers, primarily gamma-tocopherol at approximately 33-79mg/100g oil), which serve as natural antioxidants. ALA bioavailability from chia oil is moderate; conversion to long-chain omega-3s (EPA, DHA) in humans is limited (estimated 0.2-8% conversion to EPA, <0.1% to DHA), meaning it does not directly substitute for marine-sourced omega-3s. The standardized extract form (EurOmega-3) implies quality-controlled ALA concentration above commodity chia oil.

Preparation & Dosage

No clinically studied dosage ranges are specified for EurOmega-3 or its forms (extract, powder, standardized). While chia seeds contain 30-39% oil with up to 68% ALA, standardization percentages and dosing from clinical trials are absent. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Fish oil omega-3s, vitamin E, turmeric, astaxanthin, CoQ10

Safety & Interactions

ALA-rich chia seed oil is generally well tolerated at typical supplemental doses (1–3 g/day), with the most common adverse effects being mild gastrointestinal symptoms such as bloating, loose stools, and nausea. EurOmega-3 may have additive blood-thinning effects when combined with anticoagulants (warfarin, heparin) or antiplatelet drugs (aspirin, clopidogrel), warranting physician consultation before concurrent use. Individuals with hypotension or those taking antihypertensive medications should use caution, as high-dose omega-3 supplementation can modestly lower blood pressure. Pregnancy and lactation safety for this specific extract has not been formally studied, and women in these groups should consult a healthcare provider before use.